REPORT ID 6339

Global Irritable Bowel Syndrome (IBS) Research Report 2017-2022

Publish Date
26-Dec-17
Pages
113
Format
Electronic (PDF)

This report studies the Irritable Bowel Syndrome market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Irritable Bowel Syndrome market by product type and applications/end industries.


The major players in global Irritable Bowel Syndrome market include 
Allergan
Valeant Pharmaceuticals
Takeda
Sucampo Pharmaceuticals
McNeil Consumer Healthcare
Sebela Pharmaceuticals
Astellas Pharmaceuticals
IM HealthScience

Geographically, this report is segmented into several key Regions, with revenue, market share and growth rate of Irritable Bowel Syndrome in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
Japan
RoW

On the basis of product, the Irritable Bowel Syndrome market is primarily split into 
IBS-D Drug
IBS-C Drug 
Other

On the basis on the end users/applications, this report covers 
Women
Men
 
 
			   
Table of Contents

1 Irritable Bowel Syndrome Market Overview	1
1.1 Product Overview and Scope of Irritable Bowel Syndrome	1
1.2 Irritable Bowel Syndrome Segment by Types (Product Category)	2
1.2.1 Global Irritable Bowel Syndrome Revenue and Growth Rate (%) Comparison by Types (Product Category) (2016-2022)	2
1.2.2 Global Irritable Bowel Syndrome Market Share (%) by Types (Product Category) in 2016	3
1.2.3 IBS-D Drug	4
1.2.4 IBS-C Drug	4
1.2.5 Other	5
1.3 Global Irritable Bowel Syndrome Segment by Applications	5
1.3.1 Global Irritable Bowel Syndrome Sales Comparison by Applications (2012-2022)	5
1.3.2 Women	7
1.3.3 Men	7
1.4 Global Irritable Bowel Syndrome Market by Regions (2012-2022)	8
1.4.1 Global Irritable Bowel Syndrome Market Size (M USD) Comparison by Regions (2012-2022)	8
1.4.2 North America Irritable Bowel Syndrome Status and Prospect (2012-2022)	9
1.4.3 Japan Irritable Bowel Syndrome Status and Prospect (2012-2022)	10
1.4.4 Europe Irritable Bowel Syndrome Status and Prospect (2012-2022)	11
1.4.5 RoW Irritable Bowel Syndrome Status and Prospect (2012-2022)	12
1.5 Global Irritable Bowel Syndrome Market Size (2012-2022)	13
2 Global Irritable Bowel Syndrome Market Competition by Manufacturers	14
2.1 Global Irritable Bowel Syndrome Revenue and Market Share by Manufacturers (2016-2017)	14
2.2 Global Irritable Bowel Syndrome Gross Margin by Manufacturers (2016-2017)	16
2.3 Manufacturers Irritable Bowel Syndrome Headquarter, Sales Area, Product Types	17
2.4 Irritable Bowel Syndrome Market Competitive Situation and Trends	19
2.4.1 Irritable Bowel Syndrome Market Concentration Rate	19
2.4.2 Irritable Bowel Syndrome Revenue Market Share (%) of Top 3 and Top 5 Manufacturers in 2016	20
2.4.3 Mergers & Acquisitions, Expansion	21
3 Global Irritable Bowel Syndrome Revenue by Regions (2012-2017)	23
3.1 Global Irritable Bowel Syndrome Revenue and Market Share (%) by Regions (2012-2017)	23
3.2 Global Irritable Bowel Syndrome Revenue and Gross Margin (%) (2012-2017)	26
3.3 North America Irritable Bowel Syndrome Revenue and Gross Margin (%) (2012-2017)	27
3.4 Europe Irritable Bowel Syndrome Revenue, Price and Gross Margin (2012-2017)	27
3.5 Japan Irritable Bowel Syndrome Revenue, Price and Gross Margin (2012-2017)	27
3.6 RoW Irritable Bowel Syndrome Revenue, Price and Gross Margin (2012-2017)	28
4 Global Irritable Bowel Syndrome Revenue Size by Types	29
4.1 Global Irritable Bowel Syndrome Revenue and Market Share by Types (2012-2017)	29
4.2 Global Irritable Bowel Syndrome Growth by Type (2012-2017)	31
5 Global Irritable Bowel Syndrome Market Analysis by Applications	32
5.1 Global Irritable Bowel Syndrome Sales and Market Share by Applications (2012-2017)	32
5.2 Global Irritable Bowel Syndrome Sales Growth Rate by Applications (2012-2017)	34
6 Global Irritable Bowel Syndrome Manufacturers Profiles/Analysis	35
6.1 Allergan	35
6.1.1 Company Basic Information, Key Products and Sales Area	35
6.1.2 Irritable Bowel Syndrome Product Category, Application and Specification	36
6.1.3 Allergan Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	37
6.2 Valeant Pharmaceuticals	38
6.2.1 Company Basic Information, Key Products and Sales Area	38
6.2.2 Irritable Bowel Syndrome Product Category, Application and Specification	39
6.2.3 Valeant Pharmaceuticals Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	40
6.3 Takeda	40
6.3.1 Company Basic Information, Key Products and Sales Area	40
6.3.2 Irritable Bowel Syndrome Product Category, Application and Specification	41
6.3.3 Takeda Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	42
6.4 Sucampo Pharmaceuticals	42
6.4.1 Company Basic Information, Key Products and Sales Area	42
6.4.2 Irritable Bowel Syndrome Product Category, Application and Specification	43
6.4.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	44
6.5 McNeil Consumer Healthcare	45
6.5.1 Company Basic Information, Key Products and Sales Area	45
6.5.2 Irritable Bowel Syndrome Product Category, Application and Specification	46
6.5.3 McNeil Consumer Healthcare Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	46
6.6 Sebela Pharmaceuticals	47
6.6.1 Company Basic Information, Key Products and Sales Area	47
6.6.2 Irritable Bowel Syndrome Product Category, Application and Specification	48
6.6.3 Sebela Pharmaceuticals Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	48
6.7 Astellas Pharmaceuticals	49
6.7.1 Company Basic Information, Key Products and Sales Area	49
6.7.2 Irritable Bowel Syndrome Product Category, Application and Specification	50
6.7.3 Astellas Pharmaceuticals Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	51
6.8 IM HealthScience	51
6.8.1 Company Basic Information, Key Products and Sales Area	51
6.8.2 Irritable Bowel Syndrome Product Category, Application and Specification	52
6.8.3 IM HealthScience Irritable Bowel Syndrome Revenue and Gross Margin (2016-2017)	53
7 Irritable Bowel Syndrome Manufacturing Cost Analysis	54
7.1 Irritable Bowel Syndrome R&D Cost Analysis	54
7.1.1 Clinical Phase Costs	55
7.1.2 Capitalized Costs	56
7.1.3 United States Irritable Bowel Syndrome Medical Cost	57
7.2 Proportion of Manufacturing Cost Structure	57
7.2.1 Raw Materials	58
7.2.2 Labor Cost	58
7.2.3 Manufacturing Expenses	63
8 Industrial Chain, Sourcing Strategy and Downstream Buyers	69
8.1 Irritable Bowel Syndrome Industrial Chain Analysis	69
8.2 Upstream Raw Materials Sourcing	69
8.3 Downstream Buyers	70
9 Marketing Strategy Analysis, Distributors/Traders	71
9.1 Marketing Channel	71
9.1.1 Direct Marketing	71
9.1.2 Indirect Marketing	71
9.1.3 Marketing Channel Development Trend	71
9.2 Market Positioning	72
9.2.1 Pricing Strategy	72
9.2.2 Brand Strategy	73
9.3 Distributors/Traders List	74
10 Market Effect Factors Analysis	75
10.1 Irritable Bowel Syndrome Facts and Dynamic	75
10.1.1 FDA Approves Two Therapies to Treat IBS-D in 2015	75
10.1.2 Irritable Bowel Syndrome Facts	76
10.2 Consumer Needs/Customer Preference Change	78
10.3 Economic/Political Environmental Change	79
11 Global Irritable Bowel Syndrome Market Forecast (2017-2022)	87
11.1 Global Irritable Bowel Syndrome Sales Revenue (M USD) Forecast (2017-2022)	87
11.2 Global Irritable Bowel Syndrome Revenue (M USD) Forecast by Regions (2017-2022)	87
11.2.1 North America Irritable Bowel Syndrome Revenue (M USD) Forecast (2017-2022)	89
11.2.2 Europe Irritable Bowel Syndrome Revenue (M USD) Forecast (2017-2022)	90
11.2.3 Japan Irritable Bowel Syndrome Revenue (M USD) Forecast (2017-2022)	91
11.2.4 RoW Irritable Bowel Syndrome Revenue (M USD) Forecast (2017-2022)	92
11.3 Global Irritable Bowel Syndrome Sales Revenue (M USD) Forecast by Type (2017-2022)	92
11.4 Global Irritable Bowel Syndrome Revenue Forecast by Application (2017-2022)	94
12 Research Findings and Conclusion	96
13 Methodology and Data Source	97
13.1 Methodology/Research Approach	97
13.1.1 Research Programs/Design	97
13.1.2 Market Size Estimation	98
13.1.3 Market Breakdown and Data Triangulation	99
13.2 Data Source	100
13.2.1 Secondary Sources	100
13.2.2 Primary Sources	101
13.3 Disclaimer	102
13.4 Author List	103